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Saharan Africa. This method allows high throughput genotyping and simultaneous
detection of 14 high‐risk and two low‐risk HPV types, by PCR amplification of HPV
DNAs in a single reaction tube. In this study, we describe stepwise experiments to
validate the multiplex HPV PCR assay for determination of HPV genotypes from 104
cervical brush samples from Tanzanian women. Assay performance was evaluated by
determination of intra‐laboratory reproducibility, sensitivity, and specificity. Further
performance was assessed by comparison with the widely accepted and validated HPV
My09/My11 amplification and hybridization assay. Statistics; the Cohen kappa (κ) and
McNemar P values were used to analyze interobserver and intermethod agreement.
Overall concordance between the multiplex and line blot hybridization assays was 99%
(per sample) with a κ value equal to 0.95; and 96.49% (per detection event) with a κ
value of 0.92. Interobserver reproducibility of the assay per sample was 95.76% with κ
of 0.91. These results demonstrate that the multiplex HPV PCR assay has high analytical
sensitivity and specificity in detecting as many as 16 different HPV genotypes and that
its simplicity and low cost makes it well suited for sub‐Saharan Africa.
KEYWORDS

detection, high‐risk human papillomavirus, human papillomavirus genotypes, human papillomavirus, low‐risk human papillomavirus, multiplex polymerase chain reaction, performance, Sub‐
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1 | INTRODUCTION

of cervical cancer screening services, African women are more likely
to present with late‐stage cancers, thus causing significant treatment

Cervical cancer is the fourth most common cancer in women

expense to families and governments.3 Human papillomavirus (HPV)

worldwide (528 000 new cases), and the second most common

is one of the most common sexually transmitted infections (STIs) in

cancer in developing countries (445 000 new cases) in 2012.1 The

the world. A majority of epidemiological studies have established that

disease burden is greatest among women from low‐ and middle‐

HPV is the primary cause of cervical cancer and genital warts.4-6

income countries (LMIC) and with limited medical service re-

Persistent HPV infection with additional exposure to tobacco, oral

sources.1,2 In Sub‐Saharan Africa, the age‐standardized rate for

contraceptives and parity,7 lead to an increased risk of cervical

1

cervical cancer is approximately 35 per 100 000 women. Due to lack

dysplasia, accumulation of mutations, and integration of HPV

--------------------------------------------------------------------------------------------------------------------------This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any
medium, provided the original work is properly cited and is not used for commercial purposes.
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genomes into the host genome; which finally leads to the progression

smear collection was performed using the concave end of an Ayer’s

toward high‐grade dysplasia and cervical cancer.

spatula, samples were evenly spread on a glass slide and sprayed with

Current approaches to reduce the incidence of cervical cancer rely

fixative. Pap smear results were determined by three blinded cytologists

upon cervical cancer screening methods and prophylactic HPV

according to Bethesda classification system 2001.23 For HPV DNA

8-12

The screening methods include either visual inspection,

genotyping, cervical cells were collected from the opening of the cervix

cytology evaluation, and HPV tests. The visual inspection test consists

using a cytobrush. Each brush was put into a cryotube and stored at 4°C

of the naked eye inspection of the cervix after the application of 3% to

until DNA extraction.

vaccines.

5% acetic acid (VIA) or the Lugol iodine (VILI) using a cotton swab. The
visible changes in tissue pigmentation after solution application are
classified as positive (lesion) or negative (normal) results. The
Papanicolaou (Pap) test detects precancerous lesions at the cellular
level by identification of abnormal or large nuclei. In this method, a small
sample of cells is collected from the cervix and examined under an
optical microscope by a pathologist. However, HPV DNA testing is
considered the most objective, sensitive, and highly reproducible
cervical screening approach to date. These assays test for the presence

2.2 | DNA extraction of cervical samples
Cervical DNA was extracted from cytobrushes with 200 µL lysate
solution according to the Qiagen DNeasy Blood & Tissue Kit (Qiagen
Inc, Valencia, CA; cat no. 69506). The DNA concentrations of the
samples was determined using a NanoDrop Spectrophotometer.
Cervical DNA samples were stored at −20°C until PCR analysis.

of DNA or RNA from high‐risk (HR) HPV types in cervical cells and are
used in conjunction with cervical screening particularly when the Pap or
VIA results are inconclusive.13 HPV testing is still considered a

2.3 | Multiplex PCR assay

cotest,14-16 yet has been used as primary cervical screening in some

Sixteen HPV genotypes (6, 11, 16, 18, 30, 31, 33, 35, 39, 45, 51, 52,

European countries.17 Some limitations in using HPV testing in

56, 58, 59, and 66) were obtained from Karolinska Institute

developing countries are the cost, the laboratory infrastructure needed,

(International HPV Reference Center, Sweden). These plasmids were

and the need for trained laboratory technicians. There are several HPV

used as controls and test amplicons in the analytical experiments.

testing methods available. Multiplex HPV PCR is a common method

The cloned PGEMT was obtained from Promega (Madison, WI). The

which relies on simultaneous amplification of target DNAs of different

aminolevulinate synthase 1 (ALAS1) gene was cloned into the

molecular weights, each corresponding to a different HPV genotype.

PGEMT vector and the construct was used in the analytical,

In this study, results from an HPV multiplex PCR genotyping

sensitivity, and specificity experiments. All plasmids were confirmed

assay were compared with that of the My9/My11 hybridization assay

by restriction digest before HPV genotyping experiments. PCRs were

as the “gold standard.” In low‐income countries, often cost and

performed using a multiplex PCR kit (Qiagen Inc; Redwood City, CA),

availability make more sophisticated HPV genotyping assays18

according to manufacturer’s instructions. A previously developed

unobtainable. In addition, although there are several HPV test kits

protocol, with minor modifications, was followed.22 At least 50 ng of

available in the market, their reliability and validity still need to be

DNA sample solution (HPV DNA plasmid or clinical sample) was used

evaluated.19,20 HR HPVs are associated with cervical cancer whereas

as a template for PCR amplification. Samples were incubated at 95°C

the LR HPV types such as 6 and 11 are associated with benign genital

for 15 minutes, followed by 40 cycles of denaturation at 94°C

warts, hence both are included in the multiplex PCR assay.1,21 In this

(30 seconds), annealing at 70°C (90 seconds), and extension at 72°C

study we adapted and validated a multiplex HPV PCR assay which

(60 seconds). PCR products were analyzed on a 6% polyacrylamide

detects 14 HR HPV genotypes (16, 18, 30, 31, 33, 35, 39, 45, 51, 52,

gel electrophoresis (PAGE) in 1XTBE and stained with ethidium

56, 58, 59, and 66); and two low‐risk (LR) HPV genotypes (6 and 11)

bromide. Gel images were captured with a ChemiDoc MP Imaging

in a single reaction.22 Our performance analysis showed that the

System (Bio‐Rad; Hercules, CA). A positive genotyping result was

HPV multiplex PCR genotyping assay is a reliable low‐cost

called if a clear band was visualized on the gel. All HPV genotypes

alternative to commercial methods.

were detected by a single band except for HPV types 16 and 58,
which were detected by two separate bands.22

2 | MATERIALS AND METHODS
2.1 | Study population and specimen collection

End‐point detection limits of HPV genotype‐specific PCR was
achieved by serial dilutions of each respective HPV template DNA,
plus 1000 ng of Salmon sperm DNA as a carrier in each reaction
tube. This experiment was used to optimize each HPV genotype

The study protocol was reviewed and approved by the Institutional

primer set. End‐point detection limits were performed for individual

Review Boards of Ocean Road Cancer Institute (ORCI), Dar es Salaam,

or multiple HPV genotypes present in a single reaction tube.

Tanzania and the University of Nebraska‐Lincoln. The participant

Reproducibility experiments were repeated twice within 2 to 3

women were recruited from ORCI, Bagamoyo and Chalinze screening

weeks, by two blinded observers who read identical gel images. For

clinics, and informed consent was obtained from the women before

the purposes of the analytical performance comparisons, and for

sample collection. Women had a gynecological examination, including

training of Tanzanian lab personnel, the described genotyping

visual inspection with acetic acid and a conventional Pap test. Pap

experiments were done in the United States.
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2.4 | HPV hybridization method
PCR was performed using biotin‐labeled MY09/MY11 consensus HPV
L1 primers, in addition to biotin‐labeled human β‐globin primers, which
were used as an indicator of DNA quality as previously described.24
About 50 ng of DNA was added to each 100 µL PCR reaction and
subjected to 40 amplification cycles. One hundred and three samples
were interrogated by this method. Products were first hybridized
against the cellular control DNA, β‐globin, then against membrane
bound arrays of HPV standard DNAs. Standard DNAs included 38
different HPV types: 6/11, 16, 18, 26/69, 30, 31, 32/42, 33, 34, 35, 39,
45, 51, 52, 53, 54, 56, 57/2/27, 58, 59, 61, 62, 66, 67, 68, 70, 71, 72, 73,
81, 82, 83, 84, 85, 86/87, 90/106, 97, and 102/89. There were two
separate mixtures, mix‐1 contained 7, 13, 40, 43, 44, 55, 74, and 91,
while mix‐2 contained 3, 10, 28, 29, 77, 78, and 94. Negative specimens
for β‐globin gene amplification were excluded from the analysis. PCR
results were recorded on a 0 to 5 scale based on the signal intensity of
dot‐blots. For comparison purposes, a sample genotyped by hybridization method was considered positive only if one or more of the sixteen
HPV genotypes present in the multiplex HPV PCR assay was detected;
otherwise the sample was considered negative.

2.5 | Statistical analyses

SAMWEL

ET AL.

This initial sample size was based on resource practicality in the
absence of reliable data on the expected performance of both assays.
Agreement assessment, between methods (multiplex HPV PCR and
hybridization) and observers, was assessed by Cohen’s kappa test,
which is a standard statistical tool for assay performance comparison.
The Cohen kappa coefficient (κ) varies from 0 to 1, where 0 to 0.20
indicates slight agreement, 0.21 to 0.40 fair agreement, 0.41 to 0.60
moderate agreement, 0.61 to 0.80 substantial agreement and 0.81 to
1 near perfect agreement. The Cohen kappa tests were performed
per sample or per event, where an event is considered to be a specific
HPV genotyping call, including a negative call. Contingency tables
were used to calculate sensitivity and specificity values with 95%
confidence intervals (CIs). The McNemar statistical test is a second
tool for assessment of different assay methods. A McNemar test with
a P value of 0.05 is considered significant, however when there is
perfect agreement, and there are zero discordances, then a P value of
1 is still considered significant.25 Clinical sensitivity was calculated as
the proportion of women with high‐grade lesions (ASC‐H and HSIL)
tested as positive by mPCR or the hybridization method. Clinical
specificity was calculated as the proportion of women who tested
negative among those without high‐grade lesions (NILM‐LSIL).

3 | RESULTS

All statistical analyses were carried out using SAS software, version
9.4 (Cary, NC) and Excel 2016 (Microsoft, Seattle, WA). For purposes

The multiplex HPV PCR assay utilizes amplified products from 16

of the assay performance analyses, we chose a sample size of 104.

different HPV genotypes which map to different regions in the linear

F I G U R E 1 Schematic diagram of PCR products mapped on HPV genome. Each of the 16 PCR products of the different HPV genotypes are
shown mapped to different open‐reading frames on the linear representation of HPV genome. The black arrows indicate the size of each
amplicon. HPV, human papillomavirus; PCR, polymerase chain reaction
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that the multiplex HPV PCR assay possesses high specificity in
detecting each of the six HPV genotypes with no exhaustion of PCR
reagents.
The agreement charts for comparison between observer calls
using the Multiplex HPV PCR assay are shown in Figure 4. For the
“per sample” comparison (Figure 4A), the chart shows an almost
perfect agreement (dark gray shading), with only a small partial
agreement region (light gray shading) for the negative and positive
results. The proportion of agreement “per sample” analysis was 99%
(103/104 samples), and the Cohen kappa coefficient was 0.978 (95%
CI, 0.934‐1.000). The McNemar P value was 0.3173. Regarding the
“per event” (per genotype) comparison, the proportion of agreement
was 97.4% (114 of 117 events), with a κ coefficient value of 0.946
(95% CI, 0.885‐1.000) (Figure 4B). The corresponding McNemar
P value was 0.5637. The exact agreement regions, shown in Figure
4B, are slightly smaller than those in the “per sample” graph (Figure
4A) due to an increased number of “events” counted. These results
indicate that there is excellent agreement between the detection
methods. The results of this comparison is summarized in Table 2.
Figure 5 shows the comparison of detection of 103 cervical
samples between multiplex HPV PCR (filled circles) and hybridization
(open triangles) methods. In this analysis, one of the samples was not
F I G U R E 2 Determination of the end‐point detection limit of each
of the 16 HPV genotypes using the multiplex PCR assay. Ten‐fold
serial dilutions of the internal control (IC: aminolevulinate synthase
1, ALAS1) or each of the HPV DNAs were subjected to amplification.
HPV genotypes −6, 11, 16(L), 18, 30, 31, 33, 39, 45, and 58 were
detected at 1 to 10 copies per reaction, whereas HPV genotypes −16
(U), 35, 52, 56, 59, and 66 were detected at 10 to 100 copies per
reaction. The dilutions of PCR templates is indicated above each lane
(108 to 1 viral copy per reaction). Neg, indicates a reaction without
HPV DNA added. ALAS1, aminolevulinate synthase 1; HPV, human
papillomavirus; PCR, polymerase chain reaction

considered because there was a disagreement between observers’
calls for the multiplex assay. Our results showed that 4 out of 103
samples were discordant. Specifically, two cervical samples, which
were HPV negative by the hybridization method, were found to have
HPV types 33 and 66 by the multiplex assay. These corresponded to
samples number 5 and 73, respectively. Furthermore, two additional
HPV genotypes were detected in samples number 20 and 54, which
were not detected by the hybridization method: HPV types 11, 18,
and 66 (mPCR); and HPV 33 and 66 (mPCR), respectively (Figure 5).
In essence, these results suggest the HPV mPCR method has superior
sensitivity.

HPV genome (Figure 1). HPV16 has two PCR products, a lower

Figure 6 shows the agreement charts for the comparison between

HPV16 band (L) (217 bp), and an upper HPV16 band (U) (397 bp). The

the two genotyping detection methods. The proportion of agreement

analytical sensitivity of detection of each of the 16 different HPV

per sample was 98% (101 of 103 samples), and the Cohen kappa

genotypes was analyzed by PAGE, as shown in Figure 2. The end‐

coefficient obtained was 0.955 (95% CI, 0.891‐1.000) (Figure 6A). The

point detection limit of HPV genotypes 6, 11, 16(L), 18, 30, 31, 33,

corresponding McNemar score was P = 0.3173. The proportion of

39, 45 and 58 ranged from 1 to 10 copies; and 10 to 100 copies for

agreement of the per‐event analysis was 96.5% (109 of 113 events),

HPV genotypes 16(U), 35, 52, 56, 59, and 66. The number of copies

while the κ coefficient was 0.923 (95% CI, 0.849‐0.997) (Figure 6B).

per reaction determined by the multiplex HPV PCR assay were

The McNemar score was P = 0.5637. Overall, results in both cases

comparable to that obtained from real‐time PCR and capillary

indicate almost perfect agreement between the Multiplex HPV PCR

electrophoresis (CE) methods and gel electrophoresis (Table 1). Real‐

and HPV hybridization assays. Each of the McNemar scores is

time PCR had the lowest detection limits when compared with the

significant up to a value of 1. These results indicate excellent

other two methods. Overall, the end‐point detection limits obtained

agreement between the methods. The results of this comparison is

with the multiplex assay were comparable to the ones obtained by

summarized in Table 2.

CE. The end‐point detection limit assays of the multiplex PCR assay

Of the 104 cervical samples used, 12.50% were negative for

containing six different HPV genotypes (6, 16, 31, 33, and 52) is

intraepithelial lesion or malignancy (NILM) while the remaining had

shown in Figure 3. This figure demonstrates that the number of

atypical squamous cells of higher pathological categories (ASCUS‐

copies detected when using the mixture were similar as those

HSIL). Thirty‐three samples out of 104 samples tested positive by

detected for their respective individual HPV genotypes; 1 to 10

multiplex HPV PCR assay, none of the samples were excluded from

copies for 6, 16(L), 31, and 33 and 10 to 100 copies for HPV

the analysis as all samples had sufficient human DNA, as indicated by

genotypes 16(U) and 52 (Figure 2). In addition, these results suggest

the internal control. In testing the reproducibility of the multiplex

|
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T A B L E 1 Comparison of end‐point detection limits obtained by real‐time PCR, capillary electrophoresis, and gel electrophoresis
Detection limit (no. of molecules/reaction)
HPV type

Amplicon size, bp

Amplified region

Real‐time PCR

Capillary electrophoresis

Multiplex HPV PCR

6

263

E6

1

10‐100

1‐10

11

472

E7

1

1‐10

1‐10

16L

217

L2

1

1‐10

1‐10

16U

397

E1

1

10‐100

10‐100

18

187

E1

1

1‐10

1‐10

30

249

L2

1

1‐10

1‐10

31

360

L2

1

1‐10

1‐10

33

139

E1

1

1

1‐10

35

434

E6‐E7‐E1

1

10‐100

10‐100

39

229

E2

1

1‐10

1‐10

45

205

L2

1

1‐10

1‐10

51

299

E7‐E1

1

1‐10

1‐10

52

517

E5‐L2

1

1‐10

10‐100

56

330

LCR

1

10‐100

10‐100

58

128

E2

1

1‐10

1‐10

59

169

E6‐E7

1

10‐100

10‐100

66

277

L1‐LCR

1

10‐100

10‐100

IC

100

ALAS1

1

1

1‐10

Abbreviations: ALAS1, aminolevulinate synthase 1; HPV, human papilloma virus; PCR, polymerase chain reaction.

PCR assay, the samples were retested 2 to 3 weeks from the initial

the ability of the test to correctly identify those patients without the

test, gel analyses for genotype calls were analyzed by two

disease (LSIL‐NILM).35 The clinical sensitivity and specificity of the

independent observers.

multiplex HPV PCR and Line Blot hybridization using the Bethesda

The analytical sensitivity and specificity of the multiplex HPV

classification system 2001 were comparable.

PCR assay were 100% and 94.26%, respectively. The clinical

Table 3 shows the HPV genotyping results of both methods

sensitivity is defined as the ability of the test to correctly identify

according to the pap smears results. For the case of normal pathology

those patients with disease, in this case the patients who had pap

(NILM) both methods detected the same number of positive and

smear results of ASC‐H to HSIL. While the clinical specificity refers to

negative results. Regarding the abnormal pathology (ASCUS‐HSIL)

F I G U R E 3 The end‐point detection limit of multiple HPV templates using the multiplex PCR assay. HPV genotypes: 6, 16, 31, 33, 52, and 56
were diluted by 10‐fold serial dilution and subjected to multiplex PCR. The relative detection limit is indicated by the copy number per reaction
above each lane (106 to 1 copies per reaction). HPV, human papilloma virus; Neg, negative control (without HPV DNA); Marker, 1‐kb DNA
marker; PCR, polymerase chain reaction
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F I G U R E 4 Agreement chart for intra‐observer calls by multiplex HPV PCR assay. A, Agreement between observers per sample. B,
Agreement between observers per event. Shaded squares indicate exact agreement (dark gray), and partial agreement (light gray). HPV, human
papilloma virus; PCR, polymerase chain reaction

classification, it is shown that the mPCR assay is more sensitive than

choices depending on resource availability, while still using the same

the hybridization assay, since the HPV mPCR assay detected two

simple PCR method.
Agreement between observers was 97.4% with a κ coefficient value

more positive samples than the hybridization assay.

of 0.946 (113 of 118 events), and 99% with κ coefficient equal to 0.978
(103 of 104 samples), with a McNemar score of P = 0.3173, signifying

4 | D IS C U S S IO N

almost perfect agreement. As a matter of routine, we believe that it is
more reliable to have two independent observers do genotype calls.

The main goal of this study was to validate the analytical detection of

Table 2 shows the results of all performance assays. The HPV mPCR

HPV genotypes by the multiplex HPV PCR assay comparison with the

assay offers high reliability for detection of HPV genotypes present in a

clinically validated, WHO‐approved, HPV (My09/My11) hybridiza-

single reaction, without exhaustion of PCR reagents (shown in Table 1).

tion method. Overall, this comparison is highly concordant, consis-

This result shows that the assay can be reliable when simultaneous

tent, and reproducible. We chose to calculate the efficiency of HPV

detection of multiple HPV genotypes is required.28 Several studies

genotype detection per sample as well as per event (per genotype),

suggest that infection of multiple HPV genotypes in the cervical

so that we could determine if differing multiplicities of HPVs affected

epithelium is associated with development of cervical neoplasia.29,30 Like

detection efficiency. The assay demonstrated high analytical sensi-

most of the HPV DNA amplification tests, mPCR showed high analytical

tivity in detecting HPV DNA at very low copy number (between 10

sensitivity. Because of the extreme sensitivity of the assay, we prefer to

and 100 copies per cell), which is crucial to studying the natural

premix reagents in PCR tubes under in a PCR clean room under an

26,27

history of HPV pathogenesis and disease diagnosis.

isolation hood. We clean all work surfaces, pipettes and gloves with 10%

The down-

bleach before mixing reagents to avoid cross contamination.

stream analyses using either PAGE or CE gives the researcher

T A B L E 2 Summary of statistical tests of the HPV mPCR assay performance in comparison to the My9/My11 HPV hybridization assay
Percent agreement

Cohen kappa

McNemar

Sensitivity

Specificity

Per sample

98%

0.955

P = 0.3173

100%

94%

Per event (genotype)

96.50%

0.923

P = 0.0455

per sample

99%

0.978

P = 0.3173

Per event (genotype)

97.40%

0.946

P = 0.5637

mPCR vs My9/My11 blot

mPCR Intraobserver comparison

Abbreviations: HPV, human papilloma virus; PCR, polymerase chain reaction.
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sample, including US to Tanzanian shipping costs for 1000 premixed
reactions, the final reagent cost rises to about $3.10 per sample.
Commercial HPV genotyping kits often require expensive assay
detection equipment such as real‐time PCR machines or proprietary
detectors. For example, the Panatyper real‐time PCR kit (Panagene;
Deajeon, South Korea), which detects 20 HR‐HPVs, costs approximately $33 per sample. But this also requires a four‐color real‐time
PCR machine. A similar real‐time PCR kit (Biotivate, Cincinnati, OH)
to detect 21 HPVs, costs about $28 per sample. The more popular
HPV linear array kits cost more than $40 per sample to run. Such
assays are too expensive for sustainable clinical use in Sub‐Saharan
Africa. The advantages of the HPV multiplex PCR assay are that it
requires minimal reagents and is performed in a single reaction tube.
From PCR reaction to genotype determination takes about 4 hours.
We found that the HPV multiplex PCR assay had the ability to detect
F I G U R E 5 Comparison of the HPV genotype detection efficiency
between multiplex HPV PCR and HPV hybridization methods. The
different HPV genotypes detected are represented as filled circles
(multiplex PCR) and open triangles (hybridization method). The
results from 103 samples were compared. HPV negative results are
also shown in the plot. HPV, human papilloma virus;
PCR, polymerase chain reaction

HPV16 in African samples, despite the fact that there are known to be
Africa‐specific HPV16 variants from the region.32 Some further
optimization of this assay for African‐specific variants may improve
detection of HPV16 and perhaps other genotypes. Because of the
sensitivity, this assay may also be useful to assess the role of HPV in
Adenocarcinomas. We did a small‐scale analysis of the HPV multiplex
assay for its ability to predict clinical disease determined by pap smear.
Clearly, a thorough clinical analysis would be needed with a much larger

Comparing the HPV mPCR assay with the hybridization method

sample size to assess the clinical value of the assay.33 High sensitivity and

demonstrates almost perfect agreement for the sixteen HPV

specificity in clinical samples would suggest that the assay has potential

genotypes tested (see Table 2). The selection of HR HPV genotypes

use particularly in low‐resource clinical settings. Cervical cancer is highest

16, 51, 35, and 18 in this assay makes it useful in Sub‐Saharan African

in low income countries, thus, simple low‐cost solutions to assess HPV

countries,31 where these genotypes are highly prevalent. Since the

related disease are essential.1 The WHO has now suggested that HR

multiplex PCR assay detects most of the relevant HR‐HPVs as well as

HPV DNA testing should be prioritized over VIA. This will require well‐

the LR‐HPV which cause condylomas (HPV 6 and 11), it provides the

validated and inexpensive HPV DNA detection assays.34 The HPV

most disease‐relevant information. The multiplex HPV PCR proved

multiplex assay described here would be a good candidate for clinical use

an efficient use of resources since it has a reagent cost of only $3 per

in Sub‐Saharan Africa.

F I G U R E 6 Agreement charts for comparison of the HPV genotyping detection methods. A, Agreement chart of detection methods per
sample. B, Agreement chart of detection methods per event. Shaded squares indicate exact agreement (dark gray) and partial agreement (light
gray). HPV, human papilloma virus; PCR, polymerase chain reaction
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T A B L E 3 Comparison of Multiplex HPV PCR and hybridization
methods in relation to the pap smear results
Hybridization
Cytology

Multiplex

Normal (NILM)

Positive
Negative
Subtotal

Positive
5
0
5

Negative
0
8
8

Total
5
8
13

Abnormal (ASCUS‐HSIL)

Positive
Negative
Subtotal

25
0
25

2
63
65

27
63
90

30

73

103

Abbreviations: ASCUS‐HSIL, atypical squamous cells of higher pathological
categories; NILM, negative for intraepithelial lesion or malignancy.
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